groups compared with PBS group (Figure 1) . Hematoxylin/eosin staining demonstrated that loss of urothelial integrity in PBS group was restored in IV and BL group. Neutrophil infiltration was also decreased in IV and BL group compared with PBS group. Histological examination revealed a significant decrease in the total number of infiltrated mast cells in IV and BL rats compared with the PBS rats (p<0.05), (Figure 2).
INTRODUCTION AND OBJECTIVES:
We showed that both injections and cell sheets of isolated single bone marrow-derived cells could restore structures and functions of radiation-injured urinary bladders. However, they had some limitations. Thus, we biofabricated bone marrow-derived cell patches with a bio 3-dimentional printer, Regenova (Cyfuse Biomedical K.K., Tokyo, Japan). We determined if the patches could restore structures and functions in the irradiated urinary bladders.
METHODS: Twenty-four female 10-week-old Sprague-Dawley (SD) rats were irradiated with 2 gray once a week for 5 weeks. Bone marrow cells harvested from six male 17-week-old green fluorescence protein-transfected SD rats were cultured on collagen-coated dishes and flasks. The cultured bone marrow-derived cells were placed into Utype 96-well plates (3.0-5.0x10^4cells/100ml/well) to form spheroids. The spheroids were located on 9x9 arrayed needles of 4 mm square, and then it was accumulated with 3 layers. The accumulated spheroids were cultured in the perfusion chamber. After 7 days, the fused structures (patches) were pulled out from the needles. Each patch was transplanted into the irradiated anterior bladder wall (n¼10). As controls, sham operations were performed (n¼14). After 4 weeks, the urinary bladders were analyzed.
RESULTS: In cystometric investigations, voiding interval and micturition volume in the patch-transplantation group were higher than those in the control group. Residual volume of the patchtransplantation group was lower compared to the control. At 4 weeks after, the transplanted patches detected on the bladder walls were organized into the recipient bladders (Fig.1A) , and had blood vessels derived from the recipient tissues. In addition, there were many differentiated smooth muscle cells within the patches (Fig.1B-D) . The chub-transplanted bladders reconstructed smooth muscle layers and nerve fibers.
CONCLUSIONS: The biofabricated bone marrow-derived cell patches could reconstruct structures and improve bladder functions in the irradiated urinary bladders.
Source of Funding: None
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METHODS: This study was a randomized, blinded, shamcontrolled study in female Sprague-Dawley rats comparing intravenous treatment with 4 x 106 human MAPCs (n ¼ 11) vs. saline (n ¼ 11) at 24-hours post-SCI. Contusion SCI was induced at T8 using an Infinite Horizon Impactor (250 kilodyne impact). Bladders were manually expressed twice daily for 4 weeks post-SCI, and prophylactic antibiotic was administered for the first 5 days post-SCI. Rats with prolonged UTI symptoms or recurrent UTI episode received additional antibiotic treatment until the UTI resolved. The time and duration of the UTIs in the first 28 days post-SCI were recorded. Voiding frequency and volume were measured using metabolic cages at weeks 4, 6, 8 and 10 post-SCI.
RESULTS: During the first 4 weeks post-SCI, only 3 of 11 (27%) MAPC cell -treated SCI rats compared to 8 of 11 (73%) salinetreated SCI rats had prolonged UTIs or recurrent episodes that needed additional antibiotic treatment (p ¼ 0.03, Chi-sq). The duration of UTI was significantly shortened with the MAPC cell treatment compared to the saline treatment (2.4 vs. 5.4 days, p ¼ 0.03, t-test). The MAPC celltreated rats showed significant improvement in bladder function, evidenced by decreased voiding volume (p < 0.05, Fisher LSD, at week 8) and increased voiding frequency (p ¼ 0.05, t-test, at week 4) compared to the saline-treated controls.
CONCLUSIONS: To our knowledge, this is the first report of MAPC cell treatment decreasing the morbidity and duration of UTIs in rats with SCI. MAPC cell treatment may decrease UTIs as a result of the positive effect of treatment on voiding volume and frequency, though the decrease in UTIs occurred prior to the measurement of improvement in voiding volume and frequency makes it possible that MAPC cell treatment may decrease UTIs through a mechanism distinct from or in addition to their positive impact on bladder function (e.g., MAPC cells may enhance anti-bacterial immunity, thereby reducing UTIs). These results suggest that MAPC cell treatment of SCI patients may decrease their UTIs, improving quality of life. METHODS: We used three kinds of IC/BPS and KC rat model in order to show all major pathophysiology of IC/BPS and KC. The therapeutic effect of M-MSCs was examined by awake cystometry, immunohistochemistry staining (H&E, Toluidine blue, Masson's trichrome, TUNEL) after 1 week of MSCs injection. Additionally, we examined the expression of genes related to inflammation, mast cell infiltration and apoptosis by performing RQ-PCR analysis to show therapeutic effect underlying the benefits of M-MSC therapy after 1 week of transplantation.To confirm tumorigenesis or immune mediated transplant rejection of MSC, we performed micro-PET and autopsy after 1 year of transplantation of M-MSC. Furthermore we investigated mechanism of MSC therapy using longitudinal monitoring of infused M-MSCs using confocal micro-endoscopy and microscopy in living rat model after 6 months of transplantation of M-MSCs.
RESULTS: A single local transplantation of M-MSCs was effective to treat the IC and KC bladders as evidenced by ameliorated bladder voiding function and characteristic pathological features. In particularly, the therapeutic potency of M-MSCs was superior to that based on human umbilical cord blood-MSCs, reducing a required cell number up to 10 folds. Any adverse outcome regarding abnormal growth was not observed in either animal during 1 year investigation by micro-PET and autopsy. Longitudinal monitoring of infused M-MSCs using confocal microendoscopy and microscopy in living rat model demonstrated that living green florescent protein tagged cells keep alive and integrated as urothelium layer as well as vascular structure after 6 months of transplantation of M-MSCs.
CONCLUSIONS: This study provides the first evidence of the superior therapeutic efficacy, long-term safety, in vivo graft survival, and possible therapeutic mechanism of hESC-derived M-MSCs in preclinical studies.
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